Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

December 01, 2015 9:14 PM ET


Company Overview of Exeltis USA Dermatology, LLC

Company Overview

Exeltis USA Dermatology, LLC discovers, develops, produces, and markets medicinal products and medical devices in the United States and internationally. The company offers a range of products focusing on various therapeutic areas, such as women’s health, respiratory, dermatology, cardiology, central nervous system, ophthalmology, oncology, gastroenterology, infectious diseases and endocrinology, and others. It also offers products for women at various stages of life (contraception, pregnancy, fertility, and menopause) that include a portfolio of gynecological products to meet women’s reproductive health needs, treat associated conditions, and improve female wellbeing and quality of life. In ...

One Main Street

Suite 203

Chatham, NJ 07928

United States

Founded in 2003





Key Executives for Exeltis USA Dermatology, LLC

Co-Founder, Chief Executive Officer, President and Director
Age: 44
Vice President of Finance
Global President
Age: 62
Managing Director
Compensation as of Fiscal Year 2015.

Exeltis USA Dermatology, LLC Key Developments

Quinnova Pharmaceuticals, LLC has Changed its Name to Exeltis USA Dermatology, LLC

Quinnova Pharmaceuticals, LLC changed its name to Exeltis USA Dermatology, LLC.

Quinnova Pharmaceuticals LLC Announces Launch of ECOZA(TM) Topical Foam, 1%

Quinnova Pharmaceuticals LLC announced the launch of its recently U.S. Food and Drug Administration approved ECOZA(TM) (econazole nitrate) topical foam, 1%. ECOZA(TM) FOAM is indicated for the treatment of interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum in patients 12 years of age and older. ECOZA(TM) FOAM, a novel alternative for the treatment of interdigital tinea pedis (athletes foot between the toes), combines the proven antifungal efficacy of econazole nitrate with the skin-restoring properties of Proderm Technology(R). Proven to kill fungi that cause interdigital tinea pedis when applied once-daily for 4 weeks, its unique, alcohol-free foam delivery helps protect and restore skin, penetrating quickly and drying rapidly without the greasy residue that is common among other creams and gels. ECOZA(TM) FOAM is a prescription medicine used on the skin (topical) to treat athlete's foot that is between the toes (interdigital tinea pedis) in people 12 years of age and older. ECOZA(TM) FOAM should be applied to cover affected areas once daily for 4 weeks. ECOZA(TM) FOAM is for topical use only and is not for oral, ophthalmic, or intravaginal use. In two double-blind, parallel-group, vehicle-controlled, multicenter clinical trials, 495 subjects aged >=12 years with a clinical diagnosis of interdigital tinea pedis and fungal culture positive for a dermatophyte at baseline received ECOZA(TM) FOAM (n=246) or foam vehicle (n=249). Subjects applied ECOZA(TM) FOAM or foam vehicle once-daily for 4 weeks. The primary endpoint was proportion of subjects who achieved a complete cure (negative KOH, negative fungal culture, no evidence of clinical disease as indicated by complete resolution of all signs and symptoms) at 2 weeks post-treatment (Day 43). Secondary endpoints included mycologic cure (negative KOH and negative culture) and effective treatment (mycologic cure + no or mild erythema and/or scaling and all other signs and symptoms absent). The results from the clinical studies demonstrated that ECOZA(TM) FOAM exhibited superiority over foam vehicle for the primary and secondary endpoints and demonstrated potent antifungal activity against all of the pathogens evaluated with a high mycologic cure rate. The complete cure rate at Day 43 (2 weeks post-treatment) was higher in the ECOZA(TM) FOAM group (24.3%) than in the foam vehicle group (3.6%). In addition, higher rates of mycologic cure (67.6% vs 16.9%) and effective treatment (48.6% vs 10.8%) were observed with econazole nitrate foam 1% vs the foam vehicle. ECOZA(TM) FOAM was safe and well tolerated with a safety profile comparable with the foam vehicle. During clinical trials with ECOZA(TM) FOAM the most common adverse reactions were application site reactions, which occurred in less than 1% of subjects in both the ECOZA(TM) FOAM and vehicle arms. Click for full prescribing information.

Similar Private Companies By Industry

Company Name Region
Blairex Laboratories, Inc. United States
Surface Oncology, Inc. United States
Zone Therapeutics, Inc. United States
Met-Rx USA, Inc. United States
Millennium Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Exeltis USA Dermatology, LLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at